Capecitabine in Breast Cancer: How It Moves in the Body
Author Information
Author(s): Mader R M, Schrolnberger C, Rizovski B, Brunner M, Wenzel C, Locker G, Eichler H G, Mueller M, Steger G G
Primary Institution: University Hospital, Vienna, Austria
Hypothesis
How does capecitabine and its metabolites distribute in malignant and healthy tissues of breast cancer patients?
Conclusion
Capecitabine and its metabolites penetrate both malignant and healthy tissues with little selectivity.
Supporting Evidence
- Capecitabine showed significant higher exposure in malignant tissue compared to plasma.
- The study monitored drug levels in both blood and tissue using microdialysis.
- Patients were selected based on specific cancer treatment resistance criteria.
- Capecitabine and its metabolites equilibrated rapidly between plasma and tissue.
Takeaway
This study looked at how a cancer drug called capecitabine spreads in the body, showing it goes into both cancerous and healthy tissues.
Methodology
The study used microdialysis to monitor capecitabine and its metabolites in blood and tissue.
Potential Biases
Potential bias due to the selection of patients resistant to previous treatments.
Limitations
The study had a small sample size and focused only on specific patient demographics.
Participant Demographics
Patients aged 19-80 with advanced breast cancer and specific treatment history.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website